Lenvatinib Disappoints in Metastatic Esophageal Cancer Trial (LEAP -041)

The LEAP-014 trial investigated the efficacy of adding lenvatinib to pembrolizumab and chemotherapy in patients with metastatic esophageal squamous cell carcinoma (ESCC). Unfortunately, the results were disappointing, as the combination failed to demonstrate any survival benefit or meaningful clinical advantage. Here are the key findings and implications of the trial:

Trial Outcomes:

1. No Survival Benefit:

• The addition of lenvatinib did not improve overall survival (OS). The median OS was nearly identical between the two groups:
• Lenvatinib Group: 17.6 months
• Control Group (Pembrolizumab + Chemotherapy): 15.5 months
• The difference was statistically non-significant (Hazard Ratio [HR] = 0.92; P = .185).

2. Progression-Free Survival (PFS) Unchanged:

• The median PFS was also similar between the groups:
• Lenvatinib Group: 7.2 months
• Control Group: 6.9 months
• Again, the difference was not statistically significant (HR = 0.89; P = .075), confirming no meaningful clinical advantage in delaying disease progression.

3. Adverse Events Comparable:

• Grade 3 or higher treatment-related adverse events occurred at similar rates:
• Lenvatinib Group: 81.2%
• Control Group: 79.1%
• Common side effects included decreased neutrophil counts, nausea, diarrhea, and anemia, consistent with the known safety profiles of the drugs.

4. Trial Halted Early:

• The study was stopped prematurely due to futility. Interim analyses showed it was unlikely that lenvatinib would achieve statistical significance for improving survival outcomes.

Key Observations:

1. Lenvatinib's Lack of Efficacy:

• Despite lenvatinib's success in other cancers, such as renal cell carcinoma and endometrial carcinoma, it did not produce similar benefits in metastatic ESCC. This highlights the importance of tailoring therapies to specific cancer types.

2. Missed Opportunity for Biomarker Analysis:

• The study did not evaluate predictive biomarkers for lenvatinib response, which could have provided valuable insights into patient selection for targeted therapies. Experts believe this omission limits the ability to refine future strategies for ESCC treatment.

3. Expert Consensus:

• Leading oncologists, including Dr. Jaffer Ajani, concluded that lenvatinib does not currently have a therapeutic role in metastatic esophageal cancer based on the trial results.

Implications for Esophageal Cancer Treatment:

• No Role for Lenvatinib in ESCC: The findings indicate that lenvatinib should not be pursued further for metastatic esophageal squamous cell carcinoma.
• Focus on Other Approaches: Researchers may need to explore alternative combinations or novel therapies, potentially guided by biomarker analyses, to improve outcomes for patients with ESCC.

Transparency and Funding:

• The study was funded by Merck Sharp & Dohme LLC, with investigators disclosing financial associations with the company. This ensures transparency in reporting and highlights the industry's involvement in advancing cancer research.

Conclusion:

The LEAP-014 trial underscores the challenges of extending successful therapies from one cancer type to another. While lenvatinib has shown promise in other malignancies, it failed to deliver survival benefits in metastatic esophageal squamous cell carcinoma. Moving forward, researchers and clinicians must focus on identifying more effective, personalized treatments for this aggressive disease.